Orelabrutinib
- Generic Name
- Orelabrutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25N3O3
- CAS Number
- 1655504-04-3
- Unique Ingredient Identifier
- WJA5UO9E10
- Background
Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).
- Indication
⑴既往至少接受过一种治疗的成人套细胞淋巴瘤（MCL）患者。
⑵既往至少接受过一种治疗的成人慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）患者。
Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients
- Conditions
- CNS Lymphoma
- Interventions
- Drug: RCHOP+MTX or Thiotepa
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT06901999
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
- Conditions
- Marginal Zone Lymphoma(MZL)
- Interventions
- Drug: Obinutuzumab, Orelabrutinib and LenalidomideDrug: Obinutuzumab and Orelabrutinib
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 145
- Registration Number
- NCT06793189
CR-CHOP+X in Previously Untreated DEL
- Conditions
- DLBCL
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT06701357
- Locations
- 🇨🇳
No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, Shanghai, Shanghai, China
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
- Conditions
- Marginal Zone Lymphoma(MZL)
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Fei Li
- Target Recruit Count
- 90
- Registration Number
- NCT06700798
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT06656221
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Drug: R-CHOP Protocol
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 39
- Registration Number
- NCT06647940
- Locations
- 🇨🇳
Gansu Cancer Hospital, Lanzhou, Gansu, China
🇨🇳Dongguan People's Hospital, Dongguan, Guangdong, China
🇨🇳Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
- Conditions
- Lymphoma, B-Cell, Marginal Zone
- Interventions
- Radiation: response-adapted radiation
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-09-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT06583837
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Affiliated Hospital of Nantong University
- Target Recruit Count
- 30
- Registration Number
- NCT06530511
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, China
🇨🇳Affiliated hospital of Nantong University, Nantong, Jiangsu, China
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Target Recruit Count
- 528
- Registration Number
- NCT06516978
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Target Recruit Count
- 45
- Registration Number
- NCT06513234
- Locations
- 🇨🇳
China Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.